122 related articles for article (PubMed ID: 34761718)
1. The isocitrate dehydrogenase 1 is a potential prognostic indicator for non-small cell lung cancer patients.
Zhang X; Ma S; Chen Y; Yin Y; Bai W; Tan J; Shi G
Int J Biol Markers; 2021 Dec; 36(4):27-35. PubMed ID: 34761718
[TBL] [Abstract][Full Text] [Related]
2. Isocitrate dehydrogenase 1 is a novel plasma biomarker for the diagnosis of non-small cell lung cancer.
Sun N; Chen Z; Tan F; Zhang B; Yao R; Zhou C; Li J; Gao Y; Liu Z; Tan X; Zhou F; He MY; Shao K; Li N; Qiu B; Sun J; Yu Y; Wang S; Zhao Y; Shi X; He J
Clin Cancer Res; 2013 Sep; 19(18):5136-45. PubMed ID: 24046070
[TBL] [Abstract][Full Text] [Related]
3. The Clinical Significance of Serum MASP-2 and IDH1 in the Early Diagnosis of Non-Small Cell Lung Cancer.
Chen Y; Wu ED; Ma S; Bai WQ; Yin YJ; Shi GL
Clin Lab; 2020 Nov; 66(11):. PubMed ID: 33180422
[TBL] [Abstract][Full Text] [Related]
4. Differential expression profiling of transcripts of IDH1, CEA, Cyfra21-1, and TPA in stage IIIa non-small cell lung cancer (NSCLC) of smokers and non-smokers cases with air quality index.
Mishra A; Singh N; Shyam H; Jain M; Kumar Sahu D; Shankar P; Alam N; Kumar A; Jaiswal R; Kumar S
Gene; 2021 Jan; 766():145151. PubMed ID: 32950635
[TBL] [Abstract][Full Text] [Related]
5. New and old biomarkers in the differential diagnosis of lung cancer: Pro-gastrin-releasing peptide in comparison with neuron-specific enolase, carcinoembryonic antigen, and CYFRA 21-1.
Mauro C; Passerini R; Spaggiari L; Galetta D; Radice D; Lentati P; Sandri MT
Int J Biol Markers; 2019 Jun; 34(2):163-167. PubMed ID: 30994045
[TBL] [Abstract][Full Text] [Related]
6. Utility of isocitrate dehydrogenase 1 as a serum protein biomarker for the early detection of non-small-cell lung cancer: A multicenter in vitro diagnostic clinical trial.
Sun N; Sun S; Gao Y; Li Y; Lu Z; Yuan Z; Che Y; Huang J; Mao S; Lei Y; Zang R; Li N; Cui W; Qi J; Chen F; Gao J; Wang J; Min R; Chen Y; Shi G; Tan F; He J
Cancer Sci; 2020 May; 111(5):1739-1749. PubMed ID: 32167618
[TBL] [Abstract][Full Text] [Related]
7. [Clinical significance of serum cytokeratin 19 fragment in the prediction of chemotherapy efficacy and prognosis in patients with advanced non-small cell lung cancer].
Xu C; Liu J; Xing L; Liu S
Zhongguo Fei Ai Za Zhi; 2010 Oct; 13(10):954-61. PubMed ID: 20959068
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer.
Matsuoka K; Sumitomo S; Nakashima N; Nakajima D; Misaki N
Eur J Cardiothorac Surg; 2007 Sep; 32(3):435-9. PubMed ID: 17611117
[TBL] [Abstract][Full Text] [Related]
9. The relationship between Glasgow Prognostic Score and serum tumor markers in patients with advanced non-small cell lung cancer.
Jiang AG; Chen HL; Lu HY
BMC Cancer; 2015 May; 15():386. PubMed ID: 25956656
[TBL] [Abstract][Full Text] [Related]
10. [Clinical value of tumor-associated autoantibodies in diagnosis of early non-small cell lung cancer].
Ren Z; Ding HM; Qian X; Pan SY
Zhonghua Yu Fang Yi Xue Za Zhi; 2021 Dec; 55(12):1426-1434. PubMed ID: 34963239
[No Abstract] [Full Text] [Related]
11. [Value of Serum Tumor Marker Isocitrate Dehydrogenase 1 in the Diagnosis of Lung Cancer].
Xie H; Kong YX; Zhang Q
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2019 Dec; 41(6):813-817. PubMed ID: 31907132
[No Abstract] [Full Text] [Related]
12. Identification of isocitrate dehydrogenase 1 as a potential diagnostic and prognostic biomarker for non-small cell lung cancer by proteomic analysis.
Tan F; Jiang Y; Sun N; Chen Z; Lv Y; Shao K; Li N; Qiu B; Gao Y; Li B; Tan X; Zhou F; Wang Z; Ding D; Wang J; Sun J; Hang J; Shi S; Feng X; He F; He J
Mol Cell Proteomics; 2012 Feb; 11(2):M111.008821. PubMed ID: 22064513
[TBL] [Abstract][Full Text] [Related]
13. [The diagnostic significance of single or combination lung cancer-related serum biomarkers in high risk lung cancer patients].
Ni J; Guo Z; Zhang L
Zhonghua Nei Ke Za Zhi; 2016 Jan; 55(1):25-30. PubMed ID: 26796649
[TBL] [Abstract][Full Text] [Related]
14. Clinical evaluation and therapeutic monitoring value of serum tumor markers in lung cancer.
Wang L; Wang D; Zheng G; Yang Y; Du L; Dong Z; Zhang X; Wang C
Int J Biol Markers; 2016 Feb; 31(1):e80-7. PubMed ID: 26560853
[TBL] [Abstract][Full Text] [Related]
15. Folate Receptor-Positive Circulating Tumor Cell Detected by LT-PCR-Based Method as a Diagnostic Biomarker for Non-Small-Cell Lung Cancer.
Chen X; Zhou F; Li X; Yang G; Zhang L; Ren S; Zhao C; Deng Q; Li W; Gao G; Li A; Zhou C
J Thorac Oncol; 2015 Aug; 10(8):1163-71. PubMed ID: 26200270
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Serum MicroRNA21 and Tumor Markers in Diagnosis of Early Non-Small Cell Lung Cancer.
Sun M; Song J; Zhou Z; Zhu R; Jin H; Ji Y; Lu Q; Ju H
Dis Markers; 2016; 2016():3823121. PubMed ID: 26880855
[TBL] [Abstract][Full Text] [Related]
17. Clinical relevance of thymidine kinase for the diagnosis, therapy monitoring and prognosis of non-operable lung cancer.
Holdenrieder S; Von Pawel J; Duell T; Feldmann K; Raith H; Schollen A; Nagel D; Stieber P
Anticancer Res; 2010 May; 30(5):1855-62. PubMed ID: 20592392
[TBL] [Abstract][Full Text] [Related]
18. Clinical Evaluation of Tumor Markers for Diagnosis in Patients with Non-small Cell Lung Cancer in China.
Ma L; Xie XW; Wang HY; Ma LY; Wen ZG
Asian Pac J Cancer Prev; 2015; 16(12):4891-4. PubMed ID: 26163610
[TBL] [Abstract][Full Text] [Related]
19. [Evaluation of the application value of seven tumor-associated autoantibodies in non-small cell lung cancer based on machine learning algorithms].
Hao Y; Wu LN; Lyu YT; Liu YZ; Qin XS; Zheng R
Zhonghua Yu Fang Yi Xue Za Zhi; 2023 Nov; 57(11):1827-1838. PubMed ID: 38008573
[No Abstract] [Full Text] [Related]
20. Prognostic impact of Cyfra21-1 and other serum markers in completely resected non-small cell lung cancer.
Reinmuth N; Brandt B; Semik M; Kunze WP; Achatzy R; Scheld HH; Broermann P; Berdel WE; Macha HN; Thomas M
Lung Cancer; 2002 Jun; 36(3):265-70. PubMed ID: 12009236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
